Journal of Gastroenterology

, Volume 53, Issue 6, pp 801–802 | Cite as

Author’s reply: can budesonide form be alterative treatment for ulcerative proctosigmoiditis?

  • Makoto Naganuma
Letter to the Editor


Compliance with ethical standards

Conflict of interest disclosure

Makoto Naganuma received research grants from EA Pharma Co., Ltd. and Zeria Pharmaceutical Co., Ltd., outside the submitted manuscript.


  1. 1.
    Naganuma M, Aoyama N, Suzuki Y, et al. Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis. Crohns Colitis. 2016;10:828–36.CrossRefGoogle Scholar
  2. 2.
    Naganuma M, Aoyama N, Tada T, et al. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol. 2018;53:579–581.CrossRefPubMedGoogle Scholar
  3. 3.
    Sandborn WJ, Bosworth B, Zakko S, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015;148:740–50.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of MedicineKeio UniversityTokyoJapan

Personalised recommendations